Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Building macrolides

How Macrolide's synthetic chemistry could make more effective macrolides

Macrolide Pharmaceuticals Inc. is using a synthetic chemistry platform to generate novel macrolide antibiotics with improved efficacy over macrolides derived from natural products. The company is focusing on Gram-negative pathogens.

The first macrolide antibiotic, erythromycin, was isolated from bacteria over 50 years ago. Successive macrolides have been derived from erythromycin and are widely used for Gram-positive infections.

But macrolides have limited efficacy in Gram-negative pathogens, and resistance to the class is growing. CEO Lawrence Miller said the reasons are

Read the full 819 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers